Immunotherapy. Immunotherapy Triage

Similar documents
OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS

BC Cancer Protocol Summary for Treatment of Advanced Non- Small Cell Lung Cancer Using Pembrolizumab

BCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Nivolumab

PEMBROLIZUMAB (KEYTRUDA ) for the treatment of advanced melanoma or previously treated NSCLC

Melanoma Immunotherapy. Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management

Nursing Perspective on iraes: Patient Education, Monitoring and Management

Ipilimumab in Melanoma

ATEZOLIZUMAB (TECENTRIQ ) in urothelial carcinoma

Atezolizumab Non-small cell lung cancer

ATEZOLIZUMAB (TECENTRIQ )

Immune-Mediated Adverse Events Management Handbook

CANCER IMMUNOTHERAPY. Pocket Guide

Managing Checkpoint Inhibitor Toxicities. Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute

BCCA Protocol Summary for Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab

Immunotherapy: Toxicity Management. Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital

HEY Guidelines for the management of Toxicities associated with immune checkpoint inhibitors.

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

BCCA Protocol Summary for Treatment of Metastatic or Advanced Renal Cell Carcinoma Using Nivolumab

Summary of the risk management plan (RMP) for Nivolumab BMS (nivolumab)

Immune-Related Adverse Reaction (irar) Management Guide

YOUR GUIDE TO TECENTRIQ (atezolizumab) non-small cell lung cancer (NSCLC)

DOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.

Checkpoint inhibitors: Strategies to checkmate T-cell mediated toxicity. Disclosure Statement. Learning Objectives

Summary of the risk management plan (RMP) for Opdivo (nivolumab)

Immunotherapy toxicities. Dr Fiona Taylor

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO. Avelumab 200 mg/10 ml. Concentrate for Solution for Infusion

7.3 Suggested Evaluation and Treatment for Immunerelated Adverse Events Gastrointestinal Tract

Immunotherapy in Lung Cancer

Healthcare Professional. Frequently Asked. Questions. Brochure

Important safety information to minimise the risk of immune-related adverse reactions

Discussing TECENTRIQ (atezolizumab) with your healthcare team

system to help fight cancer Working with your immune

Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor

Nivolumab and Ipilimumab

system to help fight cancer Working with your immune

Immunotherapy Treatment Developments in Medical Oncology

For the Patient: USMAVPEM

Nivolumab. Nivolumab

For the Patient: USMAVNIV

Immunotherapy toxicity guidelines

BCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab

NECN CHEMOTHERAPY HANDBOOK PROTOCOL

Package leaflet: Information for the patient. Bavencio 20 mg/ml concentrate for solution for infusion avelumab

Nivolumab Ipilimumab Combination Therapy

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS

Adverse effects of Immunotherapy. Asha Nayak M.D

Risk Minimisation Information for Healthcare Professionals. Guide for Prescribing

For the Patient: USMAVFIPI

WARNINGS AND PRECAUTIONS - COMBINATION OF OPDIVO AND YERVOY

Clinical Guideline. SPEG MCN Protocols Sub Group SPEG Steering Group

Management of Immune Checkpoint Inhibitor Related Toxicities

Complications of Immunotherapy

You should read this leaflet carefully and keep it in a safe place to refer to it later. WHAT IS OPDIVO USED FOR

Nivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions

For the Patient: ULUAVPMB

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS

Managing Adverse Events Associated with Immuno-oncologic Agents

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04

NCCP Chemotherapy Regimen

Ipilimumab Monotherapy

Immune-Mediated Adverse Reactions Management Guide

MANAGEMENT OF IMMUNOTHERAPY RELATED GI AND HEPATIC ADVERSE EVENTS

Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma

Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

BC Cancer Protocol for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel

CANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center

LEMTRADA REMS Education Program for Healthcare Facilities

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

Have a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

Immune-related Adverse Events (IrAEs)

Pembrolizumab 200mg Monotherapy

1-844-FAX-A360 ( )

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

NEOFEN 60 mg suppository

Nivolumab Monotherapy 240mg -14 days

UMN request : information to be made public Page 1

REFERRAL GUIDELINES GASTROENTEROLOGY

Fever in Lupus. 21 st April 2014

NURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet)

Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services

Managing immune related toxicity. Karijn Suijkerbuijk May 27 th 2017

KEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the

Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs

Approach to the Patient with Liver Disease

Rituximab (Rituxan )

PATIENT INFORMATION LEAFLET DYNARB RANGE

PHARMA DYNAMICS CLOPIDOGREL 75 mg PATIENT INFORMATION LEAFLET

HIGHLIGHTS OF PRESCRIBING INFORMATION

WHAT IS OPDIVO USED FOR

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

Guidelines for Management of Immunotherapy-Related Adverse Events

ENAL VEIN ROMBOSIS WHAT WAS IT? DR.JANANI SANKAR UNIT DR. KEDARI NAGARJUNA, DNB P KKCTH

INVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests

Transcription:

Immunotherapy Immunotherapy Triage The most commonly used drug is Ipilimumab for Metastatic Melanoma, but use of immunotherapy is developing in lung cancer and in clinical trials. Drugs include Nivolumab and Pembrolizumab, and many other agents are expected to be licensed in the near future or are currently in clinical trial. Gastrointestinal Symptoms Diarrhoea PR Blood Loss PR Mucus Worsening Abdo Pain Skin Reactions Skin Rash +/- Itching Sores in Mouth Skin Blisters or Peels Liver Toxicity Jaundice Dark Urine Nausea and Vomiting Bleeding or Bruising Increasing ALT or Bilirubin Endocrine Symptoms Persistent or Unusual Headaches Unusual Sluggishness Feeling cold all the time Changes in Mood or Behaviour Irritability Dizziness or Fainting Pulmonary Symptoms Increasing SOB No Infection Renal Toxicity Increase in Creatinine Decreased Urine Output Neurological Toxicity Weakness of arms or legs Numbness or Tingling in Hands or Feet

Immunotherapy Related Toxicities If Immunotherapy Related Toxicities Suspected, Please Refer to Treating Cancer Centre or to the Acute Oncology Service. Immunotherapy drugs are increasingly being used to treat cancer and have a unique and varied set of autoimmune side effects which, if not recognised and treated promptly, can be fatal. The side effects, particularly those affecting the endocrine system, can sometimes occur many months after discontinuation of the drugs. These guidelines cover only the initial management of more common immunotherapy related toxicity. All patients with suspected or confirmed immunotherapy toxicity should be discussed as soon as possible with the local acute oncology service and, if indicated, with the treating oncology. 1) Diarrhoea Symptoms suggestive of serious gastrointestinal toxicity include: fever, weakness, abdominal pain, bloating, cramping pain, blood or mucous in diarrhoea, and nocturnal diarrhoea. These patients should be fully investigated and managed with care. <4 episodes of loose stool WITHOUT abdominal pain, blood, mucus or other systemic features. Mild 1. Review diet and increase oral fluids 2. Loperamide 2mg PRN (maximum 16mg/day) 3. Stool cultures (including C. Difficile) 4. Patient can be discharged if well, but inform treating oncology. 5. If grade 1 features continue beyond 4/5 days treat as moderate. Cramping abdominal pain, blood/mucus or 4 6 episodes of loose stool TIP- cramping abdo pain and blood is serious, even if diarrohea is not very frequent; always consider overall clinical features such as fever or raised WCC. Moderate 1. Admit patient. Arrange urgent Gastroenterology review ( admit gastro ward if possible) 2. Start immediate IV methylprednisolone or oral prednisolone 1mg/kg/day 3. Stool cultures (including C. Diff) 4. Abdominal X-ray 5. Urgent gastroenterology review. Seek flexible sigmoidoscopy where available 6. Discuss with treating oncology 7. If clinical deterioration consider treating as severe diarrhoea (see below)

Diarrhoea with any of the following features: severe electrolyte imbalance, severe abdominal pain or peritonitis, haemodynamic instability, blood/mucus or greater than 6 episodes of diarrhoea per day Severe 1. Admit patient 2. Start immediate IV methylprednisolone 1mg/kg/day 3. Stool cultures (including C. Diff) 4. Urgent gastroenterology review. Seek flexible sigmoidoscopy where available 5. Urgent CT chest and abdomen to exclude abscess, perforation, megacolon and previous pulmonary TB 6. Discuss with treating oncology team. Patient may require infliximab 5mg/kg if no contraindication (e.g. perforation, sepsis, prior TB), but only after discussion with oncology 2) Endocrine A number of endocrine disorders can occur, but thyroid and adrenal abnormalities are the commonest. Refer early to Endocrine team. Headache, fatigue or visual disturbance Consider hypophysitis, thyroid failure Moderate TIP- A 9am serum cortisol of <100 nmol/l is virtually diagnostic of adrenal insufficiency. 1. Pituitary blood profile includes cortisol, ACTH, TFT, prolactin, LH, FSH, testosterone (men), oestrodiol (women). Note morning cortisol most accurate. 2. Day 1 Hydrocortisone 100mg, iv tds. Day 2 Hydrocortisone 50mg, po, tds 3. If only abnormality is hypothyroidism: replace thyroxine 5. MRI brain and MRI pituitary fossa (CT brain and pituitary if MRI contra-indicated) Collapse Consider primary or secondary adrenal crisis or New onset adult type 1 diabetes mellitus +/- ketoacidosis. TIP - Delay thyroxine Severe 1. Check blood glucose, and ABG and treat with insulin if consistent with DKA 2. If unexplained shock /unwell patient (may be refractory to fluids) treat as adrenal crisis: hydrocortisone 100mg IV STAT, continue TDS & further investigations as above. Do not wait for blood results.

replacement until cortisol deficiency is either excluded or corrected if present 3. Urgent endocrinology review and discuss with treating oncology 3) Hepatitis Review medication to exclude other drug associated hepatotoxicity. AST or ALT raised but <x5 Upper Limit of Normal (ULN) and/or Bilirubin raised but <x3 ULN Mild moderate 1. Patient can probably be discharged with outpatient monitoring 2. Discuss with treating oncology 3. Check HBsAg to exclude HBV AST or ALT raised >x5 ULN and/or Bilirubin raised >x3 ULN Severe reactivation Arrange urgent Gastroenterology review (admit gastro ward if possible) 1. Urgent IV methyl-prednisolone 1mg/kg 2. Daily Liver function tests and INR 3. Check viral serology (Hep A, HBsAg, anti-hcv, CMV, EBV) and auto-antibody screen (anti-ana, SMA, LKMA, AMA, IgG, IgM, IgA) 4. Urgent referral to hepatology team and discuss with treating oncology 5. If ALT continues to rise rapidly or fails to improve: 6. Urgent USS of the liver and portal vein to exclude progressive metastatic disease or portal vein thrombus 7. Consider adding in mycophenolate 500mg BD (on advice of hepatology and oncology teams) 4) Pneumonitis/Interstitial Lung Disease Typically presents with shortness of breath, cough, hypoxia or lower grade pyrexia. Plain chest X-ray (CXR) may show lung field changes, but urgent CT pulmonary angiogram is required to define lung toxicity and exclude pulmonary embolism (PE). Any lower respiratory tract infection and/or PE should be treated according to standard protocols (LMWH preferred to warfarin).

If pneumonitis is suspected on clinical and radiological basis, arrange urgent Respiratory opinion treat with corticosteroids (1mg/kg/day of methylprednisolone equivalent) and consider atypical pneumonia. Discuss with treating oncology. 5) Dermatological Complications Rarely, Stevens-Johnsons syndrome, DRESS syndrome and toxic epidermal necrolysis have been reported. If suspected, seek urgent advice from a dermatologist. Maculopapular rash is common and the management is described below. <50% body surface area Mild moderate 1. Topical emollients with steroids (e.g. Dermovate) and antihistamines for itch. Skin advice including soap-free wash and regular aqueous cream. >50% body surface area Severe 1. 1mg/kg/day IV methylprednisolone 2. Contact on-call dermatologist to consider punch biopsy 3. Organise medical photograph 6) Neurological Complications Guillain Barre syndrome, myasthenic syndrome, aseptic meningitis and encephalitis can occur. Less well described neuromuscular syndromes involving respiratory muscle compromise have also been reported. Any patients who have had immunotherapy and present with neurological symptoms should have an urgent neurology review, and should be discussed with the treating oncology. Corticosteroids (1mg/kg/day of methylprednisolone equivalent) may be indicated. 7) Renal Complications Autoimmune renal disease in the form of nephritic and nephrotic syndromes can occur. Investigate and manage abnormal renal function as per standard procedure, including review of potentially nephrotoxic medications, rehydration if indicated, and renal tract USS if obstruction suspected. If autoimmune nephritic or nephrotic syndrome possible, seek urgent nephrology advice and consider treat with corticosteroids (1mg/kg/day of methylprednisolone equivalent) if advised. Discuss with treating oncology. 8) Other Complications Other rare toxicities include: uveitis, arthritis, myositis, pancreatitis, optic neuritis, rhabdomyolysis, haemolytic anaemia, aplastic anaemia and idiopathic thrombocytopenia purpura (ITP). If suspected, discuss with relevant specialist team, treating oncology, and consider treating with corticosteroids (1mg/kg/day of methylprednisolone equivalent) if advised.

(These toxicity guidelines have been drawn from the London Cancer Alliance, AOS Handbook)